2017
DOI: 10.1039/c7ra08625c
|View full text |Cite
|
Sign up to set email alerts
|

The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks

Abstract: Dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to counter melanoma progression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…6,7 The combination of multiple drugs with various mechanisms could be an effective strategy that might exhibit a synergistic activity. [8][9][10][11][12][13] However, the proper delivery of the combined therapy has some limitations and a proper chemical combination is highly desired due to the various physiological barriers and enzymatic processes in the body.…”
Section: Introductionmentioning
confidence: 99%
“…6,7 The combination of multiple drugs with various mechanisms could be an effective strategy that might exhibit a synergistic activity. [8][9][10][11][12][13] However, the proper delivery of the combined therapy has some limitations and a proper chemical combination is highly desired due to the various physiological barriers and enzymatic processes in the body.…”
Section: Introductionmentioning
confidence: 99%
“…However, a significant correlation was also observed in long term assays indicating that both tests are reliable markers to prove the functional impacts of metabolic reprogramming on in vitro studies and could be used interchangeably. Although the comparison of scratch test and clonogenic assay have not been reported for the impact of short and long term reduction of glucose with or without beta-hydroxybutyrate supplementation in ovarian stem-like cancer cells the similar findings were reported for other kinds of treatments in different cancers [ 14 - 16 ].…”
Section: Discussionmentioning
confidence: 55%